Zanamivir


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Inhalation Influenza A and B 10 mg twice daily for 5 days, to be started as soon as possible (w/in 48 hr) after onset of symptoms. Prophylaxis of influenza A and B Household setting: 10 mg once daily for 10 days, to be started w/in 36 hr of exposure; community outbreak: 10 mg once daily for 28 days, to be started w/in 5 days of outbreak.
Dosage Details
Inhalation/Respiratory
Influenza A and B
Adult: 10 mg (2 inhalations) bid for 5 days, admin as soon as possible (within 48 hr) after the onset of symptoms. 2 doses should be taken on 1st day of treatment provided there is at least an interval of at least 2 hr between doses, subsequent doses to be given every 12 hr.
Child: >7 yr: 10 mg (2 inhalations) bid for 5 days, admin as soon as possible (within 48 hr) after the onset of symptoms. 2 doses should be taken on 1st day of treatment, if possible, provided there is at least an interval of at least 2 hr between doses, subsequent doses to be given every 12 hr.

Inhalation/Respiratory
Prophylaxis of influenza A and B
Adult: For community outbreak: 10 mg (2 inhalations) once daily for 28 days, to be started within 5 days of outbreak. For prophylaxis in household setting: 10 mg (2 inhalations) once daily for 10 days, to be started within 36 hr of exposure.
Child: For community outbreak: >12 yr: 10 mg (2 inhalations) once daily for 28 days, started within 5 days of outbreak. For prophylaxis in household setting: ≥5 yr: 10 mg (2 inhalations) once daily for 10 days, to be started within 36 hr of exposure.
Contraindications
Hypersensitivity.
Special Precautions
Pregnancy, lactation. High risk of bronchospasm in chronic respiratory diseases. Fast-acting bronchodilator should be readily available for asthma/COPD patients; avoid in severe asthma. Bronchodilators to be inhaled before zanamivir admin. Discontinue if bronchospasm develops or there is decrease in respiratory function.
Adverse Reactions
Nasal symptoms, headache, dizziness, GI disturbances, cough, infection, rash, bronchitis. Rarely, hypersensitivity reactions, arrhythmias, bronchospasm, dyspnoea, facial oedema, seizures and syncope.
Drug Interactions
Do not admin live attenuated influenza vaccine intranasal within 2 wk before or 48 hr after zanamivir admin to improve response to vaccine.
Action
Description: Zanamivir, a sialic acid derivative, potentially inhibits viral neuraminidase of influenza virus, thus altering virus particle aggregation and release. It is active against influenza A and B virus replication.
Pharmacokinetics:
Absorption: Poorly absorbed from GI tract. Bioavailability: 2% (Oral). 10-20% of inhaled dose absorbed. Peak serum concentration: 1-2 hr (after inhalation).
Distribution: Protein binding: <10%.
Excretion: Excreted unchanged in urine. Serum half life: 2.6-5 hr.
Storage
Store at 25°C (77°F).
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Zanamivir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Relenza
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in